Effect of AI-Assisted Expressive Writing on Anxiety, Emotional Distress, and Quality of Life Among Patients Receiving Chemotherapy

Sponsor
Alexandria University
Study ID
NCT07713381
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Anxiety
  • Cancer
  • Chemotherapy

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • AI-Assisted Expressive Writing — BEHAVIORAL
    Participants will engage in an AI-assisted expressive writing program in addition to routine chemotherapy care. The intervention consists of guided writing sessions delivered through an artificial intelligence platform that provides structured prompts to facilitate emotional expression, self-reflection, and disclosure of thoughts and feelings related to cancer and chemotherapy experiences.
  • Active Comparator: Routine Care Group — OTHER
    Participants will receive routine chemotherapy care and standard nursing care provided by the oncology unit without participation in the AI-assisted expressive writing program.

Study Details

This study aims to evaluate the effect of an AI-assisted expressive writing intervention on anxiety, emotional distress, and quality of life among patients receiving chemotherapy. A mixed-methods, interventional research design will be employed. Participants will be assigned to either a study group receiving the AI-assisted expressive writing program in addition to routine care or a control group receiving routine care only. Quantitative data will be collected using the Depression Anxiety Stress Scale-21 (DASS-21) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30). Qualitative data will be obtained through semi-structured interviews to explore participants' experiences with the intervention. The findings are expected to provide evidence regarding the effectiveness of AI-assisted expressive writing as a supportive strategy for improving psychological well-being and quality of life among patients undergoing chemotherapy.

Key Dates

First listed
Jul 20, 2026
Start date
Jul 10, 2026
Status verified
Jul 2026
Primary completion
Aug 10, 2026
Completion
Sep 10, 2026

Study Design

Enrollment
100 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE

Arms

  • Experimental: AI-Assisted Expressive Writing Group
    Participants in this group will receive routine chemotherapy care in addition to the AI-assisted expressive writing program. The intervention will be delivered through guided writing sessions using an artificial intelligence platform designed to facilitate emotional expression and reflection.
  • Active Comparator: Routine Care Group

Primary Outcome Measure

Change in Anxiety and Emotional Distress Scores [ Time Frame: Baseline (Day 1) and Week 4 after intervention ]

Central Contacts

Related Studies